<i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19
SGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human <i>TP53</i> gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer. Although p53 is best known as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/4/739 |